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Abstract Myosin is an essential component of cardiac
muscle, from the onset of cardiogenesis through to the
adult heart. Although traditionally known for its role in
energy transduction and force development, recent studies
suggest that both myosin heavy-chain and myosin light-
chain proteins are required for a correctly formed heart.
Myosins are structural proteins that are not only expressed
from early stages of heart development, but when mutated
in humans they may give rise to congenital heart defects.
This review will discuss the roles of myosin, specifically
with regards to the developing heart. The expression of
each myosin protein will be described, and the effects that
altering expression has on the heart in embryogenesis in
different animal models will be discussed. The human
molecular genetics of the myosins will also be reviewed.
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Introduction
Congenital heart defects (CHDs) refer to anomalies in the
structure of the heart or great vessels that are present at
birth, and occur with a frequency of approximately 0.8 %
(one in 145 live births; British Heart Foundation
http://www.bhf.org.uk). As CHDs account for nearly one-
third of all major congenital defects, they are the most
common defect in newborns [1]. The heart forms early in
development, with a linear cardiac tube present in the
midline of the embryo at day 22 in humans. This tube
undergoes rapid morphological changes to give rise to a
correctly aligned and septated four-chambered structure by
the end of the seventh week of human embryogenesis.
Several structural proteins that are expressed in the heart
are now known to be essential for cardiogenesis. A number
of the genes to these structural proteins give rise to CHDs
upon mutation, with mutations in myosin heavy chain 6 the
first to be associated in 2005 [2]. The myosin II hexameric
molecule is composed of one pair of heavy chains and two
pairs of light chains. Myosin heavy chain (MHC) proteins
can be broadly classified into two groups; the sarcomeric
(cardiac and skeletal) and nonsarcomeric (smooth muscle
and nonmuscle) myosins. The myosin light-chain (MLC)
proteins are also classed into two groups, the essential and
regulatory light chains. This review will provide an over-
view of the roles the myosin proteins play in the
developing heart and their potential to give rise to CHDs.
The known molecular genetics in humans and animal
models will be discussed.
Myofibrillogenesis in the developing heart
The heart is the first functional organ to develop in the
vertebrate embryo due to the formation of myofibrils in
cardiomyocytes that allow for muscle contraction. The
sarcomere is the basic contractile unit of striated muscle,
which is made of thick and thin filaments responsible for
the generation of coordinated contractions. These sarco-
meres unite to form individual myofibrils that align along
the longitudinal axis of the rod-shaped cardiomyocytes.
Myofibrils are highly ordered structures brought together
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by three components: actin and myosin filaments, acces-
sory proteins of actin and myosin, and scaffolding proteins.
A sarcomere spans between two Z-discs to which the thin
filaments (actin-based) anchor and form the I-bands
(Fig. 1). Myosin, the major component of the thick fila-
ment, is interdigitated between the actin-containing thin
filaments creating A-bands in the center of the sarcomere.
Thick filaments are held in place by an M-line, the central
most structure of the sarcomere (Fig. 1). Titin is anchored
to the Z-discs at its N-terminus, and the M-line at its
C-terminus, and is thought to be important for the assembly
of the sarcomeric proteins [3] (Fig. 1). In cardiac muscle,
myofibrils from individual cells are joined by intercalated
discs, structures that are analogous to Z-discs that contain
terminal ends of actin filaments of the sarcomere, but also
act as an adherens junction between cardiomyocytes. These
intercalated discs ensure mechanical coupling within the
working myocardium [4, 5]. Any impairment within the
sarcomere can lead to dysfunction of the cardiac cells, and
is therefore potentially detrimental to heart formation and
function and hence to the embryo as it develops.
Myofibrillogenesis has become one of the most studied
phenomena in development since structural proteins of the
cardiac sarcomere were linked to myopathies (both cardiac
and skeletal) and CHDs. Investigations into myofibrillo-
genesis have utilized the chicken heart as an animal model
of the human heart. Contractions of the chicken heart ini-
tiate in the nine somite (HH10 or 36 h in ovo) embryo and
just a few hours later, the cardiovascular system is so far
developed that cardiomyocytes can pump blood throughout
the embryo [6]. In fact, major components of the sarcomere
are already expressed at the 6-somite (HH8) stage embryo
prior to heart formation, where two regions of cardiogenic
mesoderm containing premyocardial cells exist [7].
Therefore, myofibril assembly is an extremely rapid pro-
cess that occurs early in development.
Myofibrillogenesis is a process containing a number of
key steps including the formation of premyofibrils, nascent
myofibrils, and mature myofibrils [8, 9]. Firstly, proteins
assemble into structures known as premyofibrils, which
resemble mini-sarcomeres (Fig. 2a). The first marker for the
assembly of premyobrils is Z-bodies containing a-actinin
along the periphery of the cell [9]. Actin monomers are
incorporated between these Z-bodies forming actin filaments
until the myofibrils reach their mature stage [10]. In addition,
at the stage of the premyofibril, nonmuscle myosin IIB is
located distinctly between the a-actinin containing Z-bodies
(5-somite stage). Muscle myosin II is also present in these
cells, and can even be detected before myofibrils begin to
assemble (as early as the 3-somite stage), as rodlets of
0.76 lm. However, the muscle myosin remains scattered
around the nucleus of the cardiomyocytes [8]. Secondly, the
premyofibrils develop into nascent myofibrils that incorpo-
rate muscle-specific myosin II isoforms and stabilizing
proteins (Fig. 2b). As nascent myofibrils develop, muscle
myosin II begins to replace the nonmuscle isoform, and
becomes distributed throughout the myofibril (*25 lm in
length). Titin is also expressed in the myofibril at this stage
and is inserted into the Z-discs, thus playing its role in
maintaining and organizing the structures of the sarcomere,
including myosin integration [11, 12]. Finally, nascent
myofibrils begin to fuse to one another to form mature
myofibrils, which contain a highly organized structure of
A-bands and Z-discs, composed of structural sarcomeric
proteins (Fig. 2c) [8]. By the 9-somite stage (HH10), when
the first cardiac contractions have occurred, muscle myosin
II has replaced the nonmuscle myosin and appears as highly
organized bi-polar filaments of 1.6 lm in length [8, 13].
Fig. 1 Schematic
representation of a sarcomere.
The thick and thin filaments
overlap in the region of the
A-band, with the I-band formed
from the thin filaments only.
The central M-line anchors the
thick filaments and the Z-disk
the thin filaments. Titin is found
along the length of the
sarcomere. Tropomyosin and
the troponin complex interact
with actin to form part of the
thin filament
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Structure of the myosin molecule
Myosin is a large, ubiquitous, motor protein that generates
force through its interaction with actin, thus involving it in
a number of cellular processes including cytokinesis,
karyokinesis, cell migration, and muscle contraction [14].
Myosins can be divided into two distinct classes, the con-
ventional two-headed myosins and the unconventional
single-headed ones [15]. For the purpose of this review, we
will be discussing the conventional class, which can be
further subdivided into sarcomeric and nonsarcomeric
myosins. The two-headed myosins are hexameric proteins
(520 kDa) [14] comprising two myosin heavy-chain sub-
units and four myosin light-chain subunits (two regulatory
and two essential light chains) [16]. The MHCs fold
together at their C-terminus, thus forming a dimerized
coiled-coil a-helix known as the tail region. This region
contains the binding sites for myosin assembly into the
sarcomere (e.g., titin and myosin-binding protein-C), and
functions to anchor and position the motor domains of
myosin so that it interacts with actin [17]. At the N-ter-
minus, each MHC folds onto itself forming a globular head
region (subfragment-1), so that each myosin molecule
contains two globular heads. These head regions contain
the binding sites for the MLCs, ATP, actin and divalent
cations, and are called the motor region of the molecule
(Fig. 3) [14].
The subfragment-1 domain of a myosin molecule is
asymmetrical and contains a MHC folded with two MLCs.
The subfragment-1 domain can be further subdivided into
two regions; the motor domain and the regulatory domain,
which links the motor domain to the tail of the myosin
molecule [18]. Proteolysis of the myosin head reveals three
major segments; a 25-kDa N-terminal portion, a central
50-kDa segment which together form the motor domain,
and a 20-kDa C-terminal region, containing the regulatory
domain [19]. The 50-kDa segment is separated into an
upper and lower subdomain by a long, narrow cleft con-
taining an actin-binding site. The 25-kDa segment attaches
to the 50-kDa domain with an ATP-binding pocket located
at the site of attachment. The 20-kDa segment is the site to
which one regulatory and one essential light chain bind. It
is the most extended region, formed by a long a-helix [18].
This region is thought to amplify small conformational
changes into large movements needed to produce force,
and therefore, sarcomeric contraction [20].
The MLCs are comprised of two sub-families, the
essential or alkali MLC (MLC1 or ELC) and regulatory
MLC (MLC2 or RLC), which have molecular masses of 22
and 19 kDa, respectively. The MLCs wrap around the
a-helical neck region (20-kDa region) of the MHC in an
anti-parallel orientation and stabilize it. The arrangement
of MLCs relative to the ATP-binding site and actin-binding
sites of the motor domain suggests a function in creating
a longer molecule to amplify power stroke [18]. MLCs
belong to the EF-hand family, a large family of
Ca2?-binding proteins also associated with calmodulin and
troponin-C [21]. MLCs contain two Ca2?-binding EF-hand
motifs and different isoforms of MLCs may modulate the
Ca2? sensitivity of force generation and cross-bridge
kinetics (discussed below) [22]. A key difference between
MLC2 and MLC1 is a serine residue of the MLC2, which
Fig. 2 The assembly of myofibrils. a Formation of premyofibrils.
Proteins assemble into structures known as premyofibrils, which
characteristically contain a-actinin along the periphery of the cell, and
nonmuscle myosin (NMHC) scattered between the actin. b Formation
of nascent myofibrils. Muscle-specific myosin II isoforms and
stabilizing proteins become incorporated into the myofibrils, with
the myosin heavy-chain (MHC) proteins replacing NMHC. Titin is
also expressed in the myofibril at this stage. c Formation of mature
myofibrils. Nascent myofibrils fuse to form mature myofibrils,
forming a highly organized sarcomeric structure
Fig. 3 Simplified view of the relationship between the globular head
of myosin heavy chain and the thin filament. The positions of
tropomyosin and TnC, TnI, and TnT along the actin filament are
illustrated. A magnification of the globular head shows the position of
the actin-binding site, the ATP pocket, and the essential light chain
(ELC) and regulatory light chain (RLC) binding domains. MHC
myosin heavy chain, MLC myosin light chain, S1 subfragment-1, Tn
troponin
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MLC1 lacks, in the N-terminal of the peptide. MLC2 are
regulated through Ca2?-mediated phosphorylation of this
residue, which causes the MLC2 to undergo conforma-
tional changes from a compacted to an elongated form
[23]. MLC1 on the other hand has a unique N-terminal that
binds actin, thus contributing to the cross-bridge cycle
kinetics, i.e., force production [24, 25].
Myosin and the cross-bridge cycle
Force generation and muscle contraction are produced by
the cyclic interactions of the myosin head with actin fila-
ments, which is fuelled by ATP and regulated by Ca2?.
ATP controls the affinity that myosin has to actin during
the cycle. The ATP-binding site on the myosin head binds
ATP (Fig. 4a), which in turn hydrolyzes to produce ADP
and an inorganic phosphate (Fig. 4b) [26]. This causes
myosin to bind to actin (at the actin-binding site) via weak
ionic interactions (Fig. 4c). It is at this point that Ca2?
regulates the interactions between the myosin head and the
actin filament, thus initiating conformational changes in the
head region of myosin. Isomerization of the subfragment-1
unit of myosin associated with the release of the inorganic
phosphate and strong myosin-actin bonding, results in
extension of the 20-kDa lever arm of the myosin molecule,
allowing sliding of the two filaments (Fig. 4d) [27]. ADP is
then released and ATP quickly rebinds to the nucleotide-
binding region [28]. The myosin head therefore dissociates
from the actin and the cycle is complete [29, 30].
Ca2? regulates the cross-bridge cycle in striated muscle,
via the movement of tropomyosin, allowing hydrophobic
interactions to occur between myosin and actin resulting in
a tighter bond between the two molecules [31]. Therefore,
Ca2? activates the cross-bridge cycle through the thin fil-
ament regulatory system. At low levels of Ca2? within the
sarcoplasm (cytoplasm of the muscle cell), Ca2? is not
bound to the calcium-specific binding sites of troponin C
(TnC). TnC is weakly bound to TnI and TnT, but TnI is
strongly bound to actin, which holds tropomyosin in a
position that blocks the myosin-binding sites on the actin
filaments (i.e., the blocked state). When Ca2? is released by
the sarcoplasmic reticulum and intracellular concentrations
of Ca2? are increased, cross-bridge cycling is turned on.
Ca2? binds to TnC inducing a conformational change of
the troponin complex [32]. The strength of the interaction
between TnC and TnI increases, weakening the interaction
between TnT and tropomyosin, TnI and tropomyosin, and
TnI and actin. This results in TnI being pulled away from
the actin filaments. This causes a 30 shift in the tropo-
myosin molecule around the thin filament, thus exposing
myosin-binding sites that it once covered on the actin fil-
aments (Fig. 4c) [33]. Actin interacts with myosin in a
stereospecific manner (the closed state). As Ca2? contin-
uously increases, the transition from a weak to strong
cross-bridging pushes the tropomyosin further from its
Fig. 4 Schematic diagram of the cross-bridge cycle. a ATP binds to
the ATP-binding domain on the myosin head. b ATP is hydrolyzed to
ADP and a phosphate allowing the myosin head to move towards the
actin filament. c Binding of Ca2? to troponin C (TnC) results in a
conformational change in the troponin complex, allowing the
movement of tropomyosin around the actin filament (as indicated
by the purple arrows). d Release of the hydrolyzed nucleotides results
in the extension of the myosin head permitting the sliding of the
filaments (open arrows). ATP quickly rebinds to the ATP-binding site
on the myosin head, allowing dissociation of the myosin away from
the actin filament, and the cycle is repeated
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closed position on the actin filament and allows for the
complete uncovering of myosin-binding sites and leads to
power stroke and generation of force and movement [34].
Figure 3 shows the relationship myosin has to actin, the
troponin complex, and tropomyosin.
Phosphorylation of MLC2, via Ca2?/calmodulin-
dependent myosin light-chain kinases, increases the
mobility of myosin cross-bridges such that the myosin
heads move away from the thick filament towards actin
thin filaments in striated muscle fibers [35]. MLC2 phos-
phorylation increases the number of cross-bridges entering
the contractile cycle by upregulation of the actin-induced
phosphate release from the weakly bound actin-myosin
ADP-P state. This leads to an increase in Ca2? sensitivity
of the myofilament and increases the rate of force devel-
opment by increasing cross-bridge transition to the strongly
bound, force-generating state, while slowing the rate of
decay of the force-generating state [36]. In smooth muscle
and nonmuscle myosins, Ca2? release is a major determi-
nant of contraction, by activating the Ca2?/calmodulin-
dependent protein kinases that phosphorylate MLC2 [37].
This phosphorylation increases myosin ATPase activity,
resulting in cross-bridge cycling [38]. For detailed reviews
on this area, see [39–41].
The myosin heavy-chain genes
The nomenclature for the myosin II proteins has varied
within the literature. For the purposes of this review, the
genes have been named according to the nomenclature
described by the HUGO gene nomenclature committee
(http://www.genenames.org). However, as the myosin
proteins are found as hexameric molecules, it was deemed
inappropriate to name using the same terminology as the
gene. Therefore, the protein has been named using tradi-
tional terminology. To avoid confusion, but to also be
consistent with the literature, myosin heavy chain is
abbreviated to MYH when used to name genes and MHC
to name protein product.
Thirteen genes have been described for mammalian
MYH including nine sarcomeric muscle genes, three non-
muscle genes, and one smooth muscle gene. Of the
sarcomeric muscle genes, six skeletal MYH genes (MYH1,
MYH2, MYH3, MYH4, MYH8, and MYH13) are grouped
together on human chromosome 17p. The three other
striated muscle genes are cardiac MYH genes, MYH6 and
MYH7 (located on chromosome 14q11.2–q13) and MYH7B
(chromosome 20q11). There are three nonmuscle myosin II
isoforms in humans; MYH9 (chromosome 22q11.2),
MYH10 (chromosome 17p13) and MYH14 (chromosome
19q13.33). The smooth muscle gene is MYH11 (chromo-
some 16p13.11).
As will be reviewed below, the MYH genes that are
expressed to the heart in development are the sarcomeric
myosins MYH3, MYH6, MYH7, and MYH7B and the non-
sarcomeric nonmuscle myosins MYH9, MYH10, and
MYH14. The smooth muscle myosin MYH11 is absent to
the heart but present to parts of the vasculature including
the aorta. Although these genes are all expressed to the
heart or great vessels, clear roles for all in developmental
processes within the human cardiovascular system have yet
to be fully elucidated. However, model organisms have
provided interesting insights into functional roles for many
of these genes, which will be discussed below.
The protein product from the MYH3 gene is named as
embryonic myosin heavy chain (eMHC) and MYH6 is
called alpha myosin heavy chain (aMHC) in this review
though sometimes as atrial myosin heavy chain (atrial
MHC) within the literature. The MYH7 product is referred
to as beta myosin heavy chain (bMHC) in this review
though ventricular myosin heavy chain (ventricular MHC)
has also been used. Finally, the nonmuscle myosin MYH9
is referred to as NMHC IIA, MYH10 is termed NMHC IIB
and MYH14 is called NMHC IIC. The smooth muscle
myosin MYH11 product is usually named smooth muscle
myosin heavy chain (SM-MHC) within the literature and
has been used in this review. For a summary of gene
names, human chromosomal location and protein name,
see Table 1.
The myosin heavy chains and the cardiovascular system
Each myosin heavy-chain gene, which plays a role, or
potential role, in heart development is reviewed and the
expression and function each gene plays in the heart is
described for different animal models. Table 2 summarizes
the known effects of altered gene expression during car-
diogenesis. aMHC is extensively homologous across
species and Fig. 5 illustrate this between the human and the
chick, with many important functional domains showing
100 % homology. This degree of conservation across
species shows the importance of the MHC proteins.
Myosin heavy chain 3
eMHC is a skeletal myosin heavy chain protein. MYH3
transcripts are expressed in human fetal skeletal muscle
predominately, although they are also expressed by adult
skeletal muscle [42]. Roles for MYH3 have yet to be shown
in the human heart, although expression has been seen by
in situ hybridization in human 4-, 5.5-, and 7-week fetal
hearts, with RNA localized in the myocardium of the
atrium, ventricle, and sinus venosus [42]. The chick MYH3
gene is expressed in the myotome, skeletal muscle, and
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chick heart from HH12 (an early stage of cardiac looping)
through to the adult heart [42–45]. In the chick, eMHC
staining was detected in the myocardium of the atrial,
ventricular, and outflow regions of the developing heart
[42]. In addition, immunoreactivity at HH9 was detected in
a heart-specific manner, demonstrating this structural pro-
tein is expressed from the earliest stages of cardiogenesis.
Mutations in human MYH3 have been associated with
Freeman-Sheldon and Sheldon-Hall syndromes, both syn-
dromes associated with skeletal defects [46, 47]; defects to
the heart were not described. However, upon knockdown of
eMHC during early cardiogenesis in the chick, the atrial
septa and trabeculae developed abnormally [42]. Further,
both atrial and ventricular cardiomyocytes formed an
abnormal action potential (AP) and had decreased intra-
cellular K? and Ca2? transient spikes. With regards to the
ventricular cells, most were electrically inactive. These
data suggest that the structural protein eMHC is a candidate
gene for atrial septal defects (ASD; an abnormal opening
between the left and right atria chambers) and conduction
anomalies [42]. Analysis of MYH3 has not been performed
in any other animal models to our knowledge.
Myosin heavy chain 6
The expression profile of aMHC protein is similar in the
chick and human, both during development and postna-
tally. Expression is observed in skeletal muscle and the
heart during development and in the adult. During cardiac
development, although expression is found to be higher in
the atria, expression is seen in the ventricles, with the
ventricular expression decreasing relative to the atria as
development progresses [48–51]. In the adult heart, aMHC
is predominately expressed in the atrium with very low
levels found in the ventricles [48–50]. In rodents, however,
although Myh6 is predominantly expressed to the atrial
region during embryogenesis, a presence is also demon-
strated in the ventricle, and Myh6 becomes the dominant
myosin heavy-chain isoform after birth in both the atrial
and ventricular chambers [50, 52]. The orthologue to
MYH6 in zebrafish is atrial MYH, which is atrial-specific
during embryogenesis (zebrafish form a two-chambered
heart) [53]. In Xenopus (which forms a three-chambered
heart with two atria and one ventricle), the orthologue to
MYH6 is also called atrial MYH. Atrial MYH is the dom-
inant myosin heavy-chain gene during early frog
cardiogenesis, with expression throughout the myocardium
[54]. Expression is also throughout the heart of the adult
frog.
Despite intensive screening, relatively few mutations
have been found in the MYH6 gene that have been linked to
cardiomyopathy [55–57], suggesting low penetrance of this
phenotype compared to genes such as MYH7 (see below).
With regards to a role in the developing heart, aMHC was
the first structural protein that upon mutation of its gene
was associated with a CHD, with members of a family
carrying a MYH6 mutation afflicted with an ASD [2]. This
mutation caused a hydrophobic isoleucine to change to a
hydrophilic asparagine (I820N). This missense mutation
(18,429 T [ A) was in the neck region and was predicted
to affect the binding of the myosin heavy chain to its
regulatory light chain. Subsequently, a number of missense
mutations, a splice site and a nonsense mutation have been
found in MYH6 [58, 59]. Defects were not exclusive to
ASDs, with a number of other CHDs found including other
Table 1 Chromosomal location and nomenclature of myosin II
Gene
name
Human chromosomal
location
Commonly used protein name
MYH3 17pter–p11 Embryonic myosin heavy chain
(eMHC)
MYH6 14q11.2–q13 Alpha myosin heavy chain
(aMHC)
Atrial myosin heavy chain (atrial
MHC)
MYH7 14q11.2–q13 Beta myosin heavy chain (bMHC)
Ventricular myosin heavy chain
(ventricular MHC)
MYH7B 20q11 Myosin heavy chain 7B
MYH9 22q11.2 Nonmuscle myosin heavy chain
IIA (NMHC IIA)
MYH10 17p13 Nonmuscle myosin heavy chain
IIB (NMHC IIB)
MYH11 16p13.11 Smooth muscle myosin heavy
chain (SM-MHC)
MYH14 19q13.33 Nonmuscle myosin heavy chain
IIC (NMHC IIC)
MYL2 12q24.11 Myosin light chain 2 ventricular
(MLC2v)
Regulatory light chain ventricular
(RLCv)
MYL3 3p21.3–21.2 Myosin light chain 1 ventricular
(MLC1v)
Essential light chain ventricular
(ELCv)
MYL4 17q21.32 Myosin light chain 1 atrial
(MLC1a)
Essential light chain atrial (ELCa)
Embryonic myosin light chain
MYL7 12q13.2 Myosin light chain 2 atrial
(MLC2a)
Regulatory light chain atrial
(RLCa)
Only myosin heavy chains and myosin light chains that are expressed
in the heart are listed
The gene name is the approved nomenclature according to HUGO
(http://www.genenames.org)
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Table 2 Genes encoding myosin structural proteins associated with the developing heart
Gene Species Mutation/effect on gene expression CHDs associated with mutation/developmental process References
MYH3 Chick Knockdown Ab atrial and trabeculae development; enlarged heart;
abnormal AP and calcium and potassium transients
[42]
MYH6 Human I820N ASD [2]
A230P TA [58]
H252Q TGA, PFO
E501Stop TA
V700M PFO
A1366D AS, SDK, SAR, PFO
A1443D ASD
R1865Q ASD, DIVC, VSD
IVS37-2A [ G ASD, PTA [59]
R17H ASD, AVSD, SVC/CS
C539R ASD
K543R ASD
A1004S ASD
Chick Knockdown Ab atrial septal development [2, 61]
Ab trabeculae development; looping defects, EH [61]
Ab calcium transients in atrium [42]
Mouse Homozygous Death E11–12.5, heart phenotype ND [60]
Heterozygote Viable, fertile, Ab cardiac function, fibrotic lesions, Ab sarcomeres [60]
Zebrafish Weak atrium homozygous Absent contraction, Ab myofibrillogenesis in atrium [53]
Xenopus Muzak homozygous Absent myofibrils and cardiac contraction, EH [62]
MYH7 Human R281T ASD, EA [65]
Y283D ASD, VSD, pulAH [66]
Y350N EA
L390P EA, PFO
K1459N EA
N1918K Coa/BAV
E1573K VSD
1220delE EA
Chick Knockdown Ab calcium transients in atrium and ventricle [42]
EH UnD
Zebrafish Half-hearted Enlarged ventricle, fewer myofibrils, increased cardiomyocytes [70]
Medaka fish Hozuki mutant Enlarged ventricle, increased cardiomyocytes [71]
MYH10 Mouse Homozygous VSD, DORV, hypertrophic cardiac myocytes [78]
MYH11 Human IVS32 ? 1G to T TAAD [82]
R1758Q
R1241_L1264del
L1264P TAAD, PDA [83]
R1275L
R712Q
R669C PDA [84]
E1290Q
Mouse Homozygous PDA [85]
MYL2 Mouse Homozygous null Death E12.5, EH, wall thinning, Ab sarcomeres [97]
Chick Knockdown Ab cardiac looping, Ab sarcomeres [91]
MYL4 Zebrafish Knockdown Ab sarcomeres with increased length, decreased contractility [110]
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septal anomalies ventricular septal defect (VSD; an
abnormal opening between the left and right ventricular
chambers) and persistent truncus arteriosus (PTA; the
septum between the pulmonary trunk and aorta fails to
form). Functional analysis of three of the missense muta-
tions suggests that these mutations affect the normal
formation of the myofibrils, with A230P and A1366D
disrupting and H252Q enhancing assembly [58]. The
location of all these missense mutations are denoted on the
aMHC protein in Fig. 5.
A number of animal models have provided a greater
understanding of this gene. In the mouse null mutant, loss
of Myh6 led to embryonic lethality, with death occurring
at embryonic day (E) 11–12.5 [60]. However, the
embryonic heart phenotype was not characterized. In the
heterozygote animals, mice were found to be viable and
fertile with no overt phenotype. Upon detailed cardiac
function studies, however, adult heterozygotes
(12–25 weeks post-birth) had defects in cardiac contrac-
tion and relaxation with incomplete penetrance, in
comparison to wild-types [60]. Further, histological anal-
ysis revealed fibrotic lesions in heterozygote mice. In the
chick, knockdown of aMHC has demonstrated roles for
this structural protein in the initiation and/or maintenance
of the atrial septum [2, 61]. Further, development of the
ventricular trabeculae and the structural architecture of the
atrial septum, was on occasion found to be aberrant [61].
In addition, at a low penetrance, abnormal cardiac looping
and an enlarged heart were observed. Individual atrial and
ventricular cardiomyocytes from HH19 knockdown hearts
had normal AP characteristics, although cytosolic Ca2?
appeared to show modest changes in atrial (but not ven-
tricular) cells compared to controls [42]. These data
suggest that aMHC may not play a critical role in the
conduction system early in development. A loss-of-func-
tion mutation of the myh6 gene in zebrafish, called weak
atrium, is due to a frameshift mutation with the loss of
thymidine at position 4,024 [53]. Loss of myh6 in zebra-
fish caused absent atrial contraction and abnormal
myofibrillogenesis, with secondary defects consisting of
thickening of myocardial wall and a decrease in ventric-
ular lumen size [53]. Despite these defects, homozygous
weak atrium mutants can survive to adulthood and
heterozygotes appeared normal [53]. A nonsense mutation
(a C to T transition at position 3,187) of myh6 in Xenopus
tropicalis, the muzak mutant, resulted in deletion of the
coiled-coil domain [62]. These mutants have absent
myofibrils and the heart fails to contract, which led to a
number of presumed secondary effects including absent
trabeculae and cardiac valves. Heterozygotes had no dis-
cernible phenotype [62].
Myosin heavy chain 7
MYH7 is considered to be the ventricular myosin heavy-
chain gene. The bMHC protein is expressed mainly in the
ventricle in both the fetal (from 47 days, the earliest stage
analyzed) and adult human heart [48, 49]. During
embryogenesis in rodents, expression of Myh7 also
becomes ventricular-specific, seen from E7.5 in the mouse
[50, 52]. In addition, in contrast to other species, expres-
sion of Myh7 is downregulated postnatally in rodents, so
that in the adult heart Myh6 is the dominant myosin heavy-
chain gene expressed in both the atrial and ventricular
chambers [50, 52]. Outside the heart, bMHC is also
expressed in skeletal muscle during development and in the
adult. The expression profile of MYH7 in the chick is
similar to that in humans [48–51]. The presumptive func-
tional orthologue to MYH7 in Xenopus is not expressed in
the frog heart prior to chamber formation; subsequently
from stage 45 expression is seen in the regions between the
ventricle and outflow tract, and between the ventricle and
atria [54]. Ventricular- and outflow-specific expression is
seen in the adult frog. Ventricular-specific expression of
Table 2 continued
Gene Species Mutation/effect on gene expression CHDs associated with mutation/developmental process References
MYL7 Mouse Homozygous null Death E10.5–11.5, EH tube, Ab looping, Ab trabeculae,
left ventricular dilation, Ab myofibril assembly
[121]
Zebrafish Knockdown Ab sarcomeres with decreased length and contractility, EH [110]
Tell tale homozygous Ab contraction, Ab sarcomeres [120]
Only mutations and phenotypes related to cardiac development are described; mutations and phenotypes related to cardiac function e.g.,
cardiomyopathy, are not listed
Ab abnormal, AP action potential, AS aortic stenosis, ASD atrial septal defect, AVSD atrioventricular septal defect, BAV bicuspid aortic valve,
Coa coarctation of the aorta, DIVC dilated inferior vena cava, DORV double outlet right ventricle, E embryonic day, EA Epstein’s anomaly, EH
enlarged heart, ND not determined, PDA patent ductus arteriosus, PFO persistence of foramen ovale, PTA persistent truncus arteriosus, PulAH
pulmonary artery hypoplasia, SAR subaortic ridge, SDK septal dyskinesis, TA tricuspid atresia, SVC/CS abnormal drainage of superior vena cava
to coronary sinus, TAAD thoracic aortic aneurysm and/or aortic dissection, TGA transposition of the great arteries, UnD unpublished data (Dr. CS
Rutland and SL), VSD ventricular septal defect
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myh7 is seen during and upon completion of chamber
specification in the zebrafish embryo [53, 63].
Although numerous mutations in MYH7 are known to be
associated with cardiomyopathy [64], in recent years CHDs
have also been linked to this gene. A large family with left
ventricular non-compaction was found to carry a mutation
in the cDNA of the MYH7 gene at 842 G [ C, with four
individuals also afflicted with an ASD and/or Epstein’s
anomaly (EA; malformed tricuspid valve) [65]. This
mutation led to a positively charged arginine being
replaced by an uncharged threonine (R281T) and was
predicted to prevent a salt bridge from forming, leading to
instability in the myosin head. A further six missense
mutations and one small deletion (of a glutamine residue)
have also recently been described, which have been asso-
ciated with defects including ASD, VSD, and EA [66].
However, the functional significance of these mutations
still needs to be elucidated. To our knowledge, transgenic
mice with deletion of the Myh7 gene causing defects during
cardiogenesis have not been described. When our labora-
tory knocked down bMHC during early stages of heart
development in the chick, all of the morpholino positive
embryos had an enlarged heart, but the atrial septa and
other structures within the heart were found to be normal
(Dr. Catrin Rutland and SL, unpublished data). Further, as
seen with aMHC, the atrial and ventricular cardiomyocytes
had normal action potentials, although irregular Ca2?
transients were seen in atrial and ventricular cells [42].
Defects in calcium signaling may lead to defects in con-
traction of the heart, with MHC known to be important for
induction of contraction [67–69]. Two fish models have
been used to analyze the presumptive functional orthologue
to MYH7. The zebrafish has a shorter developmental period
in comparison to the medaka fish, with hatching occurring
Homo sapiens    M-T-DAQMADFGAAAQYLRKSEKERLEAQTRPFDIRTECFVPDDKEEFVKAKILSREGGK 58
Gallus gallus   MASPDAEMAAFGEAAPYLRKSEKERIEAQNKPFDAKSSVFVVHPKESFVKGTIQSKEGGK 60
* . **:** ** ** *********:***.:*** ::. ** . **.***..* *:****
Homo sapiens    VIAETENGKTVTVKEDQVLQQNPPKFDKIEDMAMLTFLHEPAVLFNLKERYAAWMIYTYS 118
Gallus gallus   VTVKTEGGETLTVKEDQVFSMNPPKYDKIEDMAMMTHLHEPAVLYNLKERYAAWMIYTYS 120
* .:**.*:*:*******:. ****:********:*.*******:***************
Homo sapiens   GLFCVTVNPYKWLPVYNAEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITG 178
Gallus gallus   GLFCVTVNPYKWLPVYNPEVVLAYRGKKRQEAPPHIFSISDNAYQFMLTDRENQSILITG 180
*****************.*** *******.***************:**************
Homo sapiens    ESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVR 238
Gallus gallus   ESGAGKTVNTKRVIQYFATIAASGEKKKEEQSGKMQGTLEDQIISANPLLEAFGNAKTVR 240
******************:*** *:: *::::.  :********.*** ***********
Homo sapiens    NDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPEL 298
Gallus gallus   NDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVTFQLPAERSYHIFYQIMSNKKPEL 300
************************************ *** ***.*******:*******
Homo sapiens    LDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIM 358
Gallus gallus   IDMLLITTNPYDYHYVSQGEITVPSIDDQEELMATDSAIDILGFSADEKTAIYKLTGAVM 360
:****:*.***** :*****::*.****.*********:*:***:::**:.:******:*
Homo sapiens    HYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSV 418
Gallus gallus   HYGNLKFKQKQREEQAEPDGTEVADKAAYLMGLNSAELLKALCYPRVKVGNEFVTKGQTV 420
****:***************** ***:*********:***.**:********:*****:*
Homo sapiens    QQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLC 478
Gallus gallus   SQVHNSVGALAKAVYEKMFLWMVIRINQQLDTKQPRQYFIGVLDIAGFEIFDFNSFEQLC 480
.**: *:************ *** ***  *:*****************************
Homo sapiens    INFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEE 538
Gallus gallus   INFTNEKLQQFFNHHMFVLEQEEYKKEGIEWEFIDFGMDLAACIELIEKPMGIFSILEEE 540
******************************* ******** ***:********:******
Homo sapiens   CMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKN 598
Gallus gallus   CMFPKATDTSFKNKLYDQHLGKSNNFQKPKPAKGKAEAHFSLVHYAGTVDYNISGWLEKN 600
******** :** ****:***********:  *** ******:********** ******
Homo sapiens  KDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLN 658
Gallus gallus  KDPLNETVIGLYQKSSVKTLALLFATYGGEAEGGGGK-KGGKKKGSSFQTVSALFRENLN 659
********:.******:* :* **::*.    *..** ****************.*****
Homo sapiens   KLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYG 718
Gallus gallus KLMANLRSTHPHFVRCIIPNETKTPGAMEHELVLHQLRCNGVLEGIRICRKGFPSRVLYA 719
***:***:************* *:**.*:: **:********************.*:**.
Homo sapiens  DFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEM 778
Gallus gallus  DFKQRYRVLNASAIPEGQFMDSKKASEKLLGSIDVDHTQYRFGHTKVFFKAGLLGLLEEM 779
**:****:**. *******:**:*.:****.*:*:**.**:*******************
Homo sapiens  RDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVIQWNIRAFMGVKNWPWMKLYFKI 838
Gallus gallus RDDKLAEIITRTQARCRGFLMRVEYRRMVERRESIFCIQYNVRSFMNVKHWPWMKLFFKI 839
**::*:.**** **:.** ***:*::::****:::: **:*:*:**.**:******:***
Homo sapiens  KPLLKSAETEKEMATMKEEFGRIKETLEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQD 898
Gallus gallus KPLLKSAESEKEMANMKEEFEKTKEELAKSEAKRKELEEKMVVLLQEKNDLQLQVQAEAD 899
********:*****.***** : ** * ****:********* *************** *
Homo sapiens NLNDAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKKDIDD 958
Gallus gallus SLADAEERCDQLIKTKIQLEAKIKEVTERAEDEEEINAELTAKKRKLEDECSELKKDIDD 959
.* ***********.*******:**:.** *****:************************
Homo sapiens  LELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQVEEDK 1018
Gallus gallus  LELTLAKVEKEKHATENKVKNFTEEMAVLDETIAKLTKEKKALQEAHQQTLDDLQVEEDK 1019
*********************:***** *** *****************:**********
Homo sapiens  VNSLSKSKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKLQL 1078
Gallus gallus VNTLTKAKTKLEQQVDDLEGSLEQEKKLRMDLERAKRKLEGDLKLAHDSIMDLENDKQQL 1079
**:*:*:*.******************:*****************:::********* **
Homo sapiens   EEKLKKKEFDINQQNSKIEDEQVLALQLQKKLKENQARIEELEEELEAERTARAKVEKLR 1138
Gallus gallus DEKLKKKDFEISQIQSKIEDEQALGMQLQKKIKELQARIEELEEEIEAERTSRAKAEKHR 1139
:******:*:*.* :*******.*.:*****:** **********:*****:***.** *
Homo sapiens  SDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKH 1198
Gallus gallus ADLSRELEEISERLEEAGGATAAQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKH 1199
:********************:.*************************************
Homo sapiens  ADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKVSRTLEDQA 1258
Gallus gallus ADSTAELGEQIDNLQRVKQKLEKEKSELKMEIDDLASNMESVSKAKANLEKMCRTLEDQL 1259
***.***********************:*:*:**::****.: ********:.****** 
Homo sapiens  NEYRVKLEEAQRSLNDFTTQRAKLQTENGELARQLEEKEALISQLTRGKLSYTQQMEDLK 1318
Gallus gallus SEIKTKEEQNQRMINDLNTQRARLQTETGEYSRQAEEKDALISQLSRGKQGFTQQIEELK 1319
.* :.* *: ** :**:.****:****.** :** ***:******:*** .:***:*:**
Homo sapiens  RQLEEEGKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYE 1378
Gallus gallus RHLEEEIKAKNALAHALQSARHDCELLREQYEEEQEAKGELQRALSKANSEVAQWRTKYE 1379
*:**** *****************:********* ***.****.****************
Homo sapiens  TDAIQRTEELEEAKKKLAQRLQDAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSN 1438
Gallus gallus TDAIQRTEELEEAKKKLAQRLQDAEEHVEAVNAKCASLEKTKQRLQNEVEDLMVDVERSN 1439
************************** ********:******:*****:***********
Homo sapiens  AAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLE 1498
Gallus gallus AACAALDKKQKNFDKILAEWKQKYEETQTELEASQKESRSLSTELFKMKNAYEESLDHLE 1499
**.*******:***************:*:***:****:*********:********:***
Homo sapiens  TFKRENKNLQEEISDLTEQLGEGGKNVHELEKVRKQLEVEKLELQSALEEAEASLEHEEG
Gallus gallus TLKRENKNLQQEIADLTEQIAEGGKAVHELEKVKKHVEQEKSELQASLEEAEASLEHEEG 1559
1558
*:********:**:*****:.**** *******:*::* ** ***::*************
Homo sapiens   KILRAQLEFNQIKAEIERKLAEKDEE
Gallus gallus  KILRLQLELNQIKSEIDRKIAEKDEEIDQLKRNHLRIVESMQSTLDAEIRSRNEALRLKK 1619
MEQAKRNHQRVVDSLQTSLDAETRSRNEVLRVKK 1618
**** ***:****:**:**:******::* **** *:*:*:*::**** *****.**:**
Homo sapiens  KMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVER 1678
Gallus gallus KMEGDLNEMEIQLSHANRMAAEAQKNLRNTQGTLKDTQIHLDDALRTQEDLKEQVAMVER 1679
*************************:::. *. ******:****:*:::****::*:***
Homo sapiens RNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMESDLTQ 1738
Gallus gallus RANLLQAEVEELRGALEQTERSRKVAEQELLDATERVQLLHTQNTSLINTKKKLETDIVQ 1739
* ******:****..:********:*****::::*******:******* ***:*:*:.*
Homo sapiens LQSEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHR 1798
Gallus gallus IQSEMEDTIQEARNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMDQTVKDLHVR 1799
:***:*:::**.**************************************:**:***: *
Homo sapiens LDEAEQIALKGGKKQLQKLEARVRELEGELEAEQK
Gallus gallus LDEAEQLALKGGKKQLQKLEARVRELEGEVDSEQKRSAEAVKGVRKYERRVKELTYQCEE 1859
RNAESVKGMRKSERRIKELTYQTEE 1858
******:**********************:::****.**:***:** ***:****** **
Homo sapiens  DKKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQ 1918
Gallus gallus DRKNILRLQDLVDKLQMKVKSYKRQAEEAEELSNVNLSKFRKIQHELEEAEERADIAESQ 1919
*:**:***********:***:********** :*.*******:****:************
Homo sapiens  VNKLRAKSRDIGAKQKMHDEE 1939
Gallus gallus VNKLRVKSREIHGKKIEE-EE 1939
*****.***:* .*:  . **
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Fig. 5 Comparison of human and chick aMHC protein sequences.
The human aMHC protein sequence (NP_002462) is compared to the
chick sequence (NP_001013415), with various structural domains
denoted on the human sequence [158]. The sequences were aligned in
ClustalW2 [159, 160]. The nucleotide (ATP)-binding pocket is in part
composed of P loop, Loop I, and Switch I with Switch II also
important in its function. The rigid relay loop is proposed to connect
the ATP binding site to the converter domain. The Strut and Loop 2
are regions that bind the upper and lower 50-kDa subdomains. Switch
II is thought to be important in forming a kink, and allowing
movement of the converter domain. The converter domain is a socket
for the carboxy terminal helical tail and is where rotation occurs
around the SH1 helix (also termed the ‘‘fulcrum’’ within the
literature), allowing bending of the molecule. The proposed domains
for the binding of titin and myosin binding protein-C (MyBP-C) are
also denoted (underlined) [161, 162]. ELC essential light chain, RLC
regulatory light chain, asterisk fully conserved residues, colon
residues with strongly similar properties conserved; period residues
with weakly similar properties conserved. Missense mutations
previously described in the human MYH6 gene [2, 58, 59] and listed
in Table 2 are denoted (boxed)
b
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at 48 h post-fertilization in the zebrafish and 8 days in the
medaka fish. The zebrafish half-hearted mutant forms due
to a C to T transition at position 3,094 bp of the cDNA,
which results in a stop codon within the tail region and
hence a non-functional truncated protein [70]. These
mutant embryos have an enlarged and distended ventricular
chamber, which fails to contract, with a normally formed
atrium. In the medaka fish, the hozuki mutants form due to
a nonsense mutation (an A to T transition) in the myh7 gene
that leads to a loss of most of the tail domain [71]. These
mutants have an enlarged ventricle, which can be seen
from cardiac looping (stage 30), with excessive cardio-
myocyte formation and fewer myofibrils in the ventricle.
The atrium appears normal and the hozuki mutant embryos
survived until hatching.
Myosin heavy chain 7b
In the adult human heart, MYH7B transcripts were detected
by RT-PCR [72] with the developing heart not investi-
gated. In mice, in situ hybridization showed that Myh7b is
expressed in the developing heart throughout the myocar-
dium of the atrial and ventricular regions [72]. Expression
is also detected in the adult heart, in somites and skeletal
muscle and tissues such as the brain and the smooth muscle
layer of large blood vessels [72–74]. In the chick, expres-
sion of MYH7B is found in the developing heart from early
stages and in the day 19 post-hatched heart, throughout the
myocardium [72], as seen in the mouse. Intriguingly, this
expression in the chick contrasts with a previous study that
detected MYH7B in the Purkinje fibers of the heart just
prior to hatching, and absent to the myocardium [72, 75].
This discrepancy is currently not understood. In Xenopus,
expression of myh7b is found in the developing heart and in
the adult [72]. Expression was also observed in somites in
both chick and Xenopus. However, despite the expression
of MYH7B is now known in a number of species, its
function is currently poorly understood.
Myosin heavy chain 9
The nonmuscle myosin, NMHC IIA, is expressed in the
human heart. However, it is expressed in the smooth
muscle, endothelial, and fibroblast cells of the heart, not in
cardiomyocytes [76]. Expression was seen at two stages;
19 weeks of development and in the adult. The expression
of NMHC IIA in the murine heart is similar to human;
smooth muscle, endothelial and fibroblast cells express
Myh9, but cardiomyocytes do not [76]. During develop-
ment, Myh9 transcripts are found in the E9.5 mouse and the
HH12 chick heart, stages when the heart is undergoing
looping in both species [77]. NMHC IIA is also expressed
in a number of other tissues such as lung, liver, and kidney.
To date, mutations in this gene have not been associated
with abnormalities in the heart.
Myosin heavy chain 10
The nonmuscle myosin protein NMHC IIB is widely
expressed. In the heart, it is expressed to smooth muscle
cells, endothelial cells, fibroblasts, and cardiomyocytes
[76]. Immunostaining found NMHC IIB to be diffuse
throughout the cytoplasm in human fetal cardiomyocytes at
19 weeks of gestation. In the adult human heart, NMHC
IIB is restricted to the Z-lines and intercalated discs [76]. A
similar expression pattern is seen for the mouse. Myh10
expression is seen in the early looping heart in both mouse
(at E9.5) and chick (at HH12) [77].
To our knowledge, mutations in the MYH10 gene have
not been found in humans. However, Myh10 ablation in the
mouse leads to embryonic lethality by E14.5 in most
embryos, with a variety of defects in the heart, including
VSDs, double-outlet right ventricle (DORV; the origin of
the aorta is abnormally located from the right ventricle)
and hypertrophic cardiomyocytes seen at high penetrance
[78]. Many null Myh10 embryos upregulated NMHC IIA, a
potential compensatory mechanism for non-heart tissues
that express Myh10. Of the null mutants that were live
born, death occurred on postnatal day 1 due to congestive
heart failure [78]. The heterozygous mice were normal.
Cardiomyocyte-specific knockout of Myh10, using the
loxP/Cre recombinase system, lead to mutant mice born
with hypertrophic myocytes [79]. These mice also had
VSDs (seen at low penetrance as expression levels were
reduced only from mid-gestation) although DORV was not
observed. Subsequently, cardiomyopathy was seen, with
the presentation of the phenotype observed between 6 and
10 months postnatally [79]. In addition, the intercalated
discs appeared wider than in controls and some of the
cardiomyocytes were multinucleated. The related non-
muscle proteins NMHC IIA and NMHC IIC were not
found to be upregulated in these mutant mice. A role for
NMHC IIB has been suggested in the spreading of
cardiomyocytes, and hence in the regulation of cell size
[80]. Other animal models have not been investigated to
date.
Myosin heavy chain 11
The protein product of the MYH11 gene is SM-MHC,
which is a contractile protein of smooth muscle cells. It is
expressed in cells derived from smooth muscle lineages;
expression is seen from the E10.5 aorta in the mouse, and
later in development in peripheral blood vessels, intestine,
bladder, and uterus [81]. Interestingly, expression is absent
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to organs such as the heart, kidney, and brain except to the
vasculature.
Mutational analysis of MYH11 was performed in two
kindreds afflicted with thoracic aortic aneurysm and/or
aortic dissection (TAAD) with three mutations detected
[82]. It was proposed that the location of the mutations may
affect the coiled-coil structure of the C-terminal region of
this smooth muscle MHC protein, and hence the assembly
of myosin thick filaments. A dominant-negative effect of
the mutations was proposed [82]. Further, symptomatic
individuals with the mutation were found to have a lower
aortic compliance and a higher pulse wave velocity, lead-
ing to a severe decrease in the elasticity of the aortic wall.
Subsequently, three MYH11 missense mutations have been
linked to individuals with TAAD and patent ductus arte-
riosus (PDA; the ductus arteriosus fails to close
postnatally) [83, 84] and rarely to isolated PDA [84].
Amino acid residue changes L1264P and R1275L, due to
mutations 3,791 T [ C and 3,824 G [ T, respectively,
were located in the coiled–coiled region whereas residue
alteration R712Q, caused by the 2,153 C [ T mutation,
was located in the ATPase head domain [83]. The R712Q
mutation was predicted to destabilize the SH1 helix and
hence prevent the motor domain and lever arm from
communicating effectively. Mutations to the coiled–coiled
domain were predicted to affect protein–protein interac-
tions. Histological analysis was performed on tissue from
affected individuals; smooth muscle cells were found to be
disorganized and show hyperplasia in the aortic media,
leading to lumen narrowing in some vessels [83]. Further
missense mutations associated with isolated PDA were
R669C (mutation 2,005 C to T in the cDNA) and E1290Q
(3,868 G to C in the cDNA) [84]. The R669C mutation was
in the globular head of SM-MHC, a region predicted to
play a role in actin binding, whereas E1290Q was located
in the tail. Other variants were also described in this study,
but were also seen in controls. Consistent with the PDA
phenotype seen in some affected individuals, Myh11
knockout mice were also found to have delayed closure of
the ductus arteriosus [85].
Myosin heavy chain 14
As with the other nonmuscle myosins, the protein product
of MYH14 is widely expressed. With regards to the heart,
NMHC IIC is expressed in cardiomyocytes of the mouse
E13.5 heart, with immunofluorescence restricted in the
intercalated discs of the adult heart [86]. Mutations in the
human MYH14 gene have not been associated with defects
in heart formation or function. Although expressed in the
heart, the Myh14 mouse knockout appeared normal and
survived to adulthood [86].
The myosin light chains
As with the myosin heavy chains, the nomenclature for the
myosin light chains has also varied within the literature. In
this review, the genes have been named according to the
nomenclature described by the HUGO gene nomenclature
committee, but as with the heavy chains, the proteins have
been named in line with the general literature. In addition,
in this review, myosin light chain is abbreviated to MYL
for the gene and MLC for the protein product.
As mentioned above, two types of MLCs exist; the
essential (MLC1; also known in the literature as ELC or
alkali MLC) and regulatory light chains (MLC2; also
known as RLC or phosphorylatable MLC). Both types are
associated with the neck region of the MHC. To date, eight
genes encode mammalian MLC, with each isoform having
a distinct expression profile. There are four MLC1 genes:
MYL1 (chromosome 2q24.11), MYL3 (chromosome
3p21.3), MYL4 (chromosome 17q21.32) and MYL6 (chro-
mosome 12q13.2). MYL1, MYL3, and MYL4 are expressed
in striated muscle, while MYL6 is a nonmuscle and smooth
muscle myosin. There are also four MLC2s: the sarcomeric
MYL2 (chromosome 12q24.11), MYL5 (chromosome
4p16.3) and MYL7 (chromosome 12q13.2), and the smooth
muscle MYL9 (chromosome 20q11.23). For a summary of
gene names, human chromosomal location and protein
name, see Table 1.
MYL3, MYL4, MYL2, and MYL7 are expressed in the
heart in a restricted manner during development and have
been shown to play a key role in cardiogenesis. Again,
the nomenclature for the MLCs has varied in the litera-
ture. MYL3 is also known as MLC1v, ELCv or VLC1,
while MYL4 is commonly referred to as the MLC1a,
embryonic MYL, ELCa or ALC1. MYL2 of the MLC2s
are also named MLC2v or RLCv, and MYL7 is known as
MLC2a or RLCa.
The myosin light chains and the cardiovascular system
The expression and function for each myosin light-chain
gene, which plays a potential role in heart development, is
discussed. The effects of altering MYL gene expression on
the developing heart are summarized in Table 2.
Myosin light chain 2
MLC2v is restricted to the ventricles, both throughout the
developing and adult human heart [87]. Expression of Myl2
is also restricted to the ventricular cardiomyocytes of the
heart tube in rodents (mouse and rat) [88, 89]. As the heart
tube begins to fold, expression is also detected in the
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proximal outflow tract; however this expression only
remains until ventricular septation commences [89]. Chick
expression of MYL2 appears similar to that of the mouse
and always remained restricted to the ventricular portion of
the heart, but is also detected as early as HH5, prior to heart
tube formation [90, 91].
Mutations of the human MYL2 gene have been associ-
ated with hypertrophic cardiomyopathy [92–97]. Lack of
Mlc2v in mice is embryonic lethal (E12.5) due to cardiac
dysfunction that results in heart failure. Hearts dissected
from these embryos showed massive cardiac enlargement,
wall thinning, dilation of the chambers, and pleural effu-
sions. Upon ultrastructural analysis of these hearts,
abnormalities in myofibril assembly were seen, displaying
disorganized alignment of the thick and thin filaments,
narrow fibers, and larger distances between Z-bands in the
homozygous null in comparison to wild-types [97].
Knockdown of MYL2 in the chick resulted in cardiac
anomalies, including irregular heart looping and, again,
poorly developed sarcomeres such that Z-discs appeared as
dense irregular shapes instead of properly formed bands
[91].
Myosin light chain 3
MLC1v expression is restricted to the ventricular segment
of the linear heart tube throughout development and in the
adult human heart [98]. This expression is also seen in the
mouse [99]. In the Xenopus, Myl3 expression is detected in
the somatic mesoderm during the tail bud stage and from
stage 31, just prior to heart tube formation, and is detected
in the precursor cells of the myocardium, but becomes
restricted to the ventricular region of the heart after looping
[100].
MLC1v is expressed in the atria of children with peri-
membranous VSDs and tetralogy of Fallot (a CHD that
involves four defects—overriding aorta, pulmonary steno-
sis, VSD, and right ventricular hypertrophy) [101].
Mutations of MYL3 have been associated with familial
hypertrophic cardiomyopathy (FHC), and, although these
mutations are rare when compared with mutations in
MYH7, the outcomes of these mutations are quite malig-
nant. Ten mutations of the MYL3 gene have been
associated with FHC, all of which have been found on the
EF-hand domain of the protein [94, 96, 102–107].
Myosin light chain 4
Human embryonic whole hearts express MLC1a, as well as
in skeletal muscle [108]. However, postnatally, protein
levels decrease to undetectable levels in the ventricles but
remain in the atria [109]. Mlc1a in Xenopus is extensively
expressed in myocardial cells at stage 31 [100]. Zebrafish
express only one MLC1, cmlc1, in a cardiac-specific
manner and this MLC1 is the orthologue to human MLC1a
[110].
A change in expression of MLC1a to other regions
apart from the atrium postnatally has been associated with
CHDs and cardiomyopathies, linked with pressure over-
load. Children with tetralogy of Fallot were shown to
express large amounts of MLC1a in the ventricles,
replacing the endogenous MLC1v of this region [111].
This was also the case in the hypertrophied left ventricle
of patients with ischemic, dilative, and hypertrophic car-
diomyopathy [112–114]. These isoform switches appear
to be compensatory mechanisms of the heart, causing
increased cycling kinetics of the cross-bridge cycle, and
hence, regulating contraction of the affected heart [22].
This isoform switch was also studied in the mouse.
Transgenic overexpression of Myl4 leads to high levels of
expression in the ventricles, replacing the endogenous
Myl3 [115]. Although the isoform shift was benign, with
no pathology observed, there was improved cardiac
function in the mouse hearts. Knockdown of cmlc1 in
zebrafish resulted in failure of the assembly of Z-bands
from the Z-bodies [110]. In addition, the thick filaments
appear less dense as they fail to align and assemble
properly into A-bands within the sarcomere during
development, increasing sarcomeric length. End systolic
ventricular volume of cmlc1 knockdowns was greater than
that of wild-types indicating the morphant hearts can
dilate but not contract sufficiently [110]. These results
suggest a vital role for MLC1 in sarcomeric assembly and
fine-tuning of cardiac contractility.
Myosin light chain 7
MLC2a is expressed in humans at high levels in the atrium
postnatally, throughout the linear heart during develop-
ment, and can also be detected in the adult ventricles, but at
lower levels [116]. In the mouse, Myl7 is initially expres-
sed throughout the linear heart tube early in development
(E7.5); however, it becomes restricted to the atria after
E12.5 [117]. Expression is similar in the rat [88]. Although
expression is seen throughout the linear heart tube, the
protein is incorporated in the myofibrils of the atria only,
not into the ventricular myofibrils [97]. The mlc2 gene is
the Xenopus orthologue of human MYL2 [118]. It is
expressed early in development in the cardiac mesoderm
and in subsequent steps of heart tube formation, looping,
and chamber septation where it is not restricted to any one
area of the myocardium [119]. Zebrafish show strong
expression of only one isoform of MLC2s in the heart,
cmcl2, which is thought to be the zebrafish orthologue of
human MLC2a [110, 120]. Cmcl2 is expressed in the 13
somite stage (prior to heart tube formation) zebrafish
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embryo, and is expressed throughout the myocardium of
the heart by the time heart looping has occurred [63].
Mutations in MYL7 have not yet been associated with
human disease to our knowledge. Myl7 null mice were
found to be embryonic lethal between E10.5–11.5, and
unusual cardiac morphogenesis was apparent in the early
linear heart tube (E7.5) such as enlargement of the heart
tube and abnormal morphogenesis in the looping heart
tube. They also presented with enlarged atria and outflow
tracts. The ventricles displayed thin walls, with underde-
veloped trabeculae and left ventricular dilation was
apparent. At the ultrastructural level, the myofibrils in the
atria were disorganized, with a lack of alignment of
the thick and thin filaments, associated with diminished
beating in the atrial chamber, while cardiomyocytes in
the ventricles appeared normal [121]. Chimeric mice of
chromosome 21, used as an animal model for Down’s
syndrome, showed post-transcriptional down-regulation of
endogenous Myl7, which was also seen in human patients
[122]. As more than 50 % of Down’s syndrome patients
have a CHD, this study suggests a potential role for MLC2a
in CHDs. Knockdown of cmcl2 using morpholino oligo-
nucleotides in the zebrafish results in a number of defects
in cardiogenesis. Assembly of the dotted Z-bodies into
Z-discs failed and previously assembled thick filaments did
not align into A-bands, with the sarcomeres of decreased
length. Cardiac contractility was reduced, as was the ven-
tricular chamber volume [110]. These data indicate that
MLC2s are important in myofibrillogenesis and cardiac
contractility. Mutations in the cmcl2 gene were also stud-
ied. The tell-tale mutation telm225 is a fully penetrant
embryonic lethal recessive mutation that perturbs cardiac
contractility in early embryonic development [120].
Although heart tube formation appears normal, with the
two heart chambers of normal size, strong peristaltic con-
tractions of the chamber seen in the wild-type are weaker in
the telm225 mutant. This is the result of disturbances of
thick filament assembly of the sarcomere, suggesting a role
for MLC2 in sarcomerogenesis [120].
The role of transcription factors in the regulation
of myosin
Structural proteins are the downstream targets of tran-
scription factors that control heart formation in a tightly
controlled manner. Therefore, considering the critical role
these transcription factors play in cardiogenesis, it is not
surprising that a number of these genes have also been
found to form CHDs when mutated. The first cardiac
transcription factor associated with a CHD was in 1998 in
the homeobox gene NKX2.5, with mutations found in
probands predominately afflicted with an ASD and
conduction defects [123]. Subsequently, mutations have
been found in numerous other cardiac transcription factors,
such as GATA4 [124], and the T-box genes TBX5 [125,
126] and TBX20 [127]. It is also of interest that many of
these transcription factors have synergistic effects, and are
upstream of other cardiac transcription factors or genes
such at the natriuretic factors NPPA (natriuretic peptide
precursor a, also known as atrial natriuretic factor) and
NPPB (natriuretic peptide precursor b, also known as brain
natriuretic factor) [128–132]. Serum response factor (SRF)
is a ubiquitous transcription factor that elicits its effect on
cardiac and smooth muscle genes by associating with its
cofactor myocardin. Myocardin is also known to interact
with a number of other cofactors [133].
As stated above, bMHC is specifically expressed to the
ventricle [48, 49]. In zebrafish, the lack of myh7 expres-
sion in the atrium is regulated by Nkx2.5 [134]. The
zebrafish homeobox transcription factor Prx2 and the
mouse Gata factors Gata4 and Gata6 have also been
shown to regulate myh7 expression [131, 134, 135].
However, in embryonic hearts isolated from compound
heterozygote Gata4/Tbx5 mice, mRNA expression of
Myh7 was found to be unaffected, unlike Myh6, which
showed decreased expression in the compound heterozy-
gote but not in the single Gata4 and Tbx5 heterozygotes
[130]. Myh6 is also regulated by important cardiac tran-
scription factors. Both GATA4 and TBX5 activate Myh6
expression in rodents in vitro [2, 132, 136]. In addition,
the transcription factor myocardin, which is a cofactor for
SRF and TBX5, activated Myh6 [137, 138]. In contrast,
Gata4/Gata6 compound heterozygote mice did not show
decreased Myh6 expression, despite these mice having a
range of heart defects [131]. Bmp-4 is also thought to be
important in the mediation of sarcomeric myosin
expression in Xenopus [139]. IRX4 (iroquois homeobox
4) is a transcription factor that is ventricular specific; it
has a role in myosin regulation by activating MYH7 to be
expressed in the ventricle while suppressing MYH6 [140].
Activation of the Myh7b mouse promoter was shown to
occur via Gata, Mef2, and E-box binding sites, with the
Mef2 site being the most important [72]. Interestingly,
other conserved regulatory elements were found to be
important in Myh7b expression, although the proteins that
bind to these sites have yet to be identified.
In comparison to the sarcomeric myosins, the regulation
of the nonsarcomeric myosins in the heart is poorly
understood. GATA6 has been shown to be important in the
activation of the smooth muscle Myh11 gene, with GATA6
forming a complex with the transcriptional coactivator
p300 [141]. In contrast to Myh6, Myh11 was not activated
by the myocardin/TBX5 complex [142]. However, myo-
cardin has been shown to activate smooth muscle Myh11
via other cofactors including SRF [142–144].
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MYLs are also regulated by a number of transcription
factors. Unlike mammals, Xenopus has only one regulatory
MYL. Enhancer elements within the promoter region of
this gene have been shown to be essential for the heart-
specific expression in Xenopus [119]. Additional in vitro
studies in Xenopus of the Gata motifs and an SRF site
within this MYL promoter region were shown to be nec-
essary for this specific expression, and over-expression of
gata6 has been associated with a lack of mlc2 expression
[119, 145]. Further, gata and srf genes were shown to act
synergistically in regulation of the regulatory myl in the
frog [119]. This is supported by another study in Xenopus
that demonstrated that regulatory myl is activated via the
srf cofactor myocardin interacting with gata4; this con-
trasted with myh6 which could be activated by each factor
independently [138]. As stated previously in this review,
MLC phosphorylation is regulated by myosin light chain
kinase (MLCK). Interestingly, Mlck is also regulated by
the cardiac transcription factor Nkx2.5 [146].
Micro RNAs in the regulation of myosin
Additional regulation of cardiac transcription factors and
myosin genes is via noncoding RNAs, notably miRNAs.
miRNAs are known to be important in a number of bio-
logical processes, such as cell proliferation, differentiation,
and apoptosis [147]. miRNAs modulate gene expression
predominately by acting as negative regulators by inducing
the degradation or inhibiting the translation of target
mRNAs. Mature miRNAs are approximately 22 nucleo-
tides long, with their formation involving two RNase III
enzymes Drosha and Dicer [148, 149]. The extent to which
miRNAs play in heart development is currently not fully
understood, though is likely to be complex, as any one
miRNA may regulate more than one target, and more than
one miRNA can bind to the same gene. The role that
miRNAs play in cardiac transcription factor regulation is
beyond the scope of this review, with a number of excellent
reviews recently published [147, 150]. However, it is
relevant to summarize the recent data demonstrating a role
for miRNAs in the regulation of the myosin genes.
Intergenic, intronic, and exonic miRNAs can occur, with
the exonic miRNAs being expressed with the host gene.
Intergenic and intronic miRNAs have their own regulatory
elements. Embryonic stem cells undergo mesodermal dif-
ferentiation to a myocardial lineage, with miR-1 and miR-
133 playing critical roles in controlling this process [151,
152]. Further, miR-1 has been shown to be important for
cardiomyocyte differentiation and its overexpression was
found to repress Myh6 [152, 153]. With regards to the myosin
genes having their own miRNAs, three intronic miRNAs
have been located within cardiac myosin heavy-chain genes.
miR-208a is located in intron 27 of the human and mouse
MYH6 gene [154], with the related miR-208b located in
intron 31 of MYH7 [73] and miR-499 is within intron 19 of
the MYH7B gene [155]. In the mouse, the expression of these
miRNAs correlates with their host genes, with miR-208a
mainly expressed in the adult heart, miR-208b predomi-
nately expressed in the developing heart and miR-499
expressed during cardiac morphogenesis and in the adult [74,
156]. Although miR-208a, miR-208b, nor miR-499 seem to
function during mouse cardiogenesis, miR-208a was shown
to be the dominant miRNA in the adult heart, by upregulating
Myh7 transcripts in response to stress [73, 154]. However, as
other larger animals express MYH6 and MYH7 differently to
mice, the expression and function of miR-208a and miR-
208b could also be different. Consistent with this, an in vitro
study using human cardiomyocytes progenitors suggests a
role for miR-499 in differentiation [153], with overexpres-
sion of miR-499 in human embryoid bodies leading to
significant upregulation of MYH7 [155].
Conclusions and future perspectives
Myosin structural proteins are expressed in a restricted
manner in the developing heart and play vital roles in early
cardiogenesis. In this review, we have shown that changes
in expression can lead to detrimental effects on the
developing heart, with a variety of phenotypes seen.
However, there remain many gaps in knowledge with as
yet a comprehensive understanding of the role myosin
heavy and light chains play in cardiogenesis still lacking.
In the future, further genetic and molecular studies will
elucidate precise roles for the myosins in heart develop-
ment and how the myosins are regulated at different
developmental stages. Such insights should improve
genetic counseling and may lead to therapeutic treatments
of CHDs, cardiomyopathies, and other cardiac anomalies.
Already myosin-activating drugs have gone on trial for the
treatment of heart failure. These activators work by
increasing the transition rate of the weakly bound acto-
myosin complex to a strongly bound one, therefore
increasing cardiac contraction [157]. A greater under-
standing of the role and regulation of myosin structural
proteins should help pave the way for creating a detailed
molecular map of heart development.
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